Built the first consumer DNA testing kit that made genetics accessible. Fought a multi-year war with the FDA, submitted 7,000 pages of evidence, and won. Created the world's largest genetic database with 15 million users willing to share deidentified data.
What Changed
The business model was fundamentally broken — DNA doesn't change, so customers bought once and never returned. The big bet on drug discovery flopped; GSK downgraded their $300M partnership to just $20M. Then a hacker exposed 7 million users' data, and instead of owning the crisis, the company blamed customers. Revenue cratered 30%.
Where it Landed
Chapter 11 bankruptcy. Stock down 98% from peak. Anne Wojcicki bought the assets for $35M through a nonprofit she controls. 1.9 million users deleted their data. The California Attorney General warned people to get out.
The Principles
1.
One-time revenue is a death sentence. If customers never come back, you're constantly chasing new ones at rising costs with no compounding.
2.
Crisis response defines you. Blaming customers for a hack you enabled destroys trust faster than the breach itself.
3.
Hype can't cover broken unit economics. Drug discovery dreams don't fix the fact that your core product has no retention.
Builder's Takeaway
3 warning signs your growth story is masking structural rot:
•
You're selling something people buy once and never need again
•
Customer acquisition costs keep rising while retention stays flat or falls
•
The 'next big thing' pivot is covering up core business decay
